Servier to collaborate with Aitia using Gemini Twins Technology to focus on Gliomas

This time, the focus is on gliomas, a broad group of brain cancers. Aitia said its Gemini Digital Twins platform combines multi-omic patient data, high-performance computing, causal learning and AI to uncover hidden biological mechanisms of disease for the discovery and genetic validation of novel drug targets. The collaboration will use Aitia’s platform, which is powered by millions of data points from patient cancer tissues, to find new treatments for gliomas. Under the agreement, the two companies will work together to discover, validate and develop novel drug candidates for glioma by combining Aitia’s Gemini Digital Twins technology with Servier’s therapeutic discovery and clinical development expertise in oncology. The work is to include exploration of the heterogeneous biology of these brain cancers, mechanisms of resistance and drug response at the individual patient level.